Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress across its oncology pipeline, including two drug candidates now moving toward clinical development …
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a series of strategic updates aimed at sharpening its development priorities and extending its financial runway. The biotechnology company has executed …
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy …
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the publication of two abstracts featuring preclinical data from its JAK2V617F mutant-selective inhibitor program and CALR-targeted degrader antibody conjugates (DACs) discovery …
Prelude Therapeutics Highlights Groundbreaking Blood Cancer Research at ASH 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the appointment of Katina Dorton to its Board of Directors, effective immediately. Dorton brings more than 30 years of experience in …
Prelude Therapeutics Appoints Katina Dorton to Board of Directors Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has shifted its strategic focus toward its oral SMARCA2 degrader, PRT7732, while reporting narrower second-quarter losses and steady progress across its oncology …
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced it will participate in two healthcare conferences in June.
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) released its first-quarter financial results, showcasing operational progress and updates across its clinical pipeline.
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, will participate in the Citizens Life Sciences Conference in New York on May 7, 2025.
Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its …
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies Read More